Physician profile
Allison Hoffritz
NPI 1932759479
$1,786.97
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,481 · 2022: $248 · 2023: $15.01 · 2024: $42.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $377.48 | 2021-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $242.89 | 2021-2022 | |
| Astellas Pharma US INC | $166.42 | 2021 | |
| Abbvie INC. | $133.50 | 2021-2022 | |
| Amgen INC. | $101.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $100.84 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.83 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $82.02 | 2021-2024 | Eliquis |
| Lilly USA, LLC | $75.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $67.83 | 2021 | |
| Paratek Pharmaceuticals, INC. | $60.30 | 2021 | |
| Dexcom, INC. | $53.56 | 2021 | |
| Abbott Laboratories | $41.05 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $29.19 | 2021-2022 | |
| Boston Scientific Corporation | $16.92 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $16.13 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.60 | 2021 | |
| Eisai INC. | $13.57 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.17 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.54 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.42 | 2021 | |
| Clarus Therapeutics INC. | $12.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.83 | 2022 | |
| Phadia US INC. | $11.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.31 | 2021 | |
| Esperion Therapeutics, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hoffritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.